{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(7)"],"submitter":["Barthold D"],"pubmed_abstract":["Importance
For people with type 2 diabetes (T2D), out-of-pocket medication costs may influence medication choice, adherence, and overall diabetes management and progression. Little is known about how these costs change as insured people enter Medicare at age 65 years, when coinsurance in the coverage gap and catastrophic phases of Part D coverage can be increased greatly by use of insulin and newer, branded medications (eg, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, and sodium-glucose cotransporter 2 inhibitors).Objective
To identify whether reaching age 65 years is associated with T2D medication out-of-pocket costs and utilization.Design, setting, and participants
This retrospective cohort study (2012-2020) featuring 7 years of follow-up u"],"journal":["JAMA network open"],"pagination":["e2420724"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11234236"],"repository":["biostudies-literature"],"pubmed_title":["Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare."],"pmcid":["PMC11234236"],"pubmed_authors":["Li J","Barthold D","Basu A"],"additional_accession":[]},"is_claimable":false,"name":"Patient Out-of-Pocket Costs for Type 2 Diabetes Medications When Aging Into Medicare.","description":"Importance
For people with type 2 diabetes (T2D), out-of-pocket medication costs may influence medication choice, adherence, and overall diabetes management and progression. Little is known about how these costs change as insured people enter Medicare at age 65 years, when coinsurance in the coverage gap and catastrophic phases of Part D coverage can be increased greatly by use of insulin and newer, branded medications (eg, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 agonists, and sodium-glucose cotransporter 2 inhibitors).Objective
To identify whether reaching age 65 years is associated with T2D medication out-of-pocket costs and utilization.Design, setting, and participants
This retrospective cohort study (2012-2020) featuring 7 years of follow-up u","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T11:24:53.208Z","creation":"2025-04-04T11:24:53.208Z"},"accession":"S-EPMC11234236","cross_references":{"pubmed":["38980673"],"doi":["10.1001/jamanetworkopen.2024.20724"]}}